Evidence map›Paper›PMID 34221544›Full record

ReviewAging and disease2021

Acute Stroke Management: Overview and Recent Updates.

Mary Hollist, Larry Morgan, Rainier Cabatbat, Katherine Au, Maaida F Kirmani, Batool F Kirmani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 99 citations in OpenAlex.

  1. Trial
  2. Arterial Glyceryl Trinitrate in Acute Ischemic Stroke After Thrombectomy for Neuroprotection (AGAIN): A Pilot Randomized Controlled Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Trial
  3. Article
  4. A methodological review of pragmatic designs in acute stroke trials.International journal of stroke : official journal of the International Stroke Society · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Mary Hollist1Memorial Healthcare Institute for Neurosciences, Owosso, MI, USA.
Larry Morgan2Bronson Neuroscience Center, Kalamazoo, MI, USA.
Rainier Cabatbat2Bronson Neuroscience Center, Kalamazoo, MI, USA.
Katherine Au3George Washington University, School of Medicine & Health Sciences, Washington DC, USA.
Maaida F Kirmani4School of Public Health Texas A&M University, College Station, TX, USA.
Batool F Kirmani5Texas A&M University College of Medicine, College Station, TX, USA.
Bronson Methodist Hospital · USFamily Healthcare · USGeorge Washington University · USSt. Joseph Medical Center · USTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a leading cause of morbidity and mortality in the United States. Whether hemorrhagic or ischemic, stroke leads to severe long-term disability. Prior to the mid-1990s, the treatment offered to a patient who presented with an acute stroke was mainly limited to antiplatelets. The lack of adequate treatment, in particular, one without reperfusion contributed to the disability that ensued. There have been many advances in stroke care within the past two decades, especially with the acute management of ischemic stroke. Even with these advances, it is quite alarming that only a fraction of patients receives acute stroke treatment. Numerous trials were conducted to broaden treatment eligibility in hopes that more patients can be treated acutely and safely. These trials have tested both the time window for IV tPA and endovascular therapy (EVT). Acute stroke management is moving from a universal time window approach to a concept of tissue preservation. Specifically, preserving cerebral blood flow, the penumbra, and reducing the risk of a second event. This movement is being executed through the use of multimodal CT and MRI, as well as individualizing treatment to our patients. Minimizing the initial effect of stroke changes the outcome and leads to an increased likelihood of functional independence. In this review, we discuss the recent updates of acute ischemic stroke management in regards to mechanical thrombectomy as well as thrombolytics including tenecteplase.

Indexed as

Intravenous tissue plasminogen activator (IV tPA)mechanical thrombectomystroketenecteplasethrombolytics

Identifiers

PMID34221544
PMCPMC8219501
OpenAlexW3181649585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.